<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960205</url>
  </required_header>
  <id_info>
    <org_study_id>ZXL-201308</org_study_id>
    <nct_id>NCT01960205</nct_id>
  </id_info>
  <brief_title>Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity</brief_title>
  <official_title>Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Medical Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the effect of Saxagliptin in the newly diagnosed
      people with pre-diabetes and obesity besides lifestyle intervention ,there to evaluate DPP 4
      inhibitors of reversing pre-diabetes curative effect to normal blood sugar, and observe its
      influences on the targets of obesity related metabolic abnormalities, to explore new ways
      for intervention on populations with pre-diabetes and obesity .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Materials and Methods:                                                        This is a
      perspectiveness ,randomized, opening study, patients will be randomly assigned to the
      standarddose Saxagliptin  group ,the lifestyle intervention group,the Metformin group and
      the low dose Saxagliptin group with a 6-month treatment period.

      Oral glucose tolerance test  will  examined before and 6 months post-treatment during the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>oral glucose tolerance test</measure>
    <time_frame>Change of Blood sugar from baseline at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Standarddose Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin  5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lifestyle intervention for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin  500 mg (tablet) ,500mg three times  a day  and lifestyle intervention for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>5mg a day for 6 months</description>
    <arm_group_label>Standarddose Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>2.5 mg a day for 6 months</description>
    <arm_group_label>low dose Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>500mg three times a day for 6 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>melbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lifestyle intervention</intervention_name>
    <description>lifestyle intervention for 6 months</description>
    <arm_group_label>Lifestyle intervention</arm_group_label>
    <other_name>living way intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Newly diagnosed insulin resistance or glucose intolerance .

        2.20 to 70 years of age.

        3.BMI≥28kg/m2，or BMI＞25kg/m2 beside waistline≥80cm（female)，≥90cm(male).

        Exclusion Criteria:

          1. Under Diabetes Mellitus treatment.

          2. Allergy to dipeptidyl peptidase 4 (DPP-4) inhibitors .

          3. Active heart failure.

          4. Unwilling or unable to sign inform consents.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinli Zhou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinli Zhou, MD,PhD</last_name>
    <phone>15168889976</phone>
    <email>zhouxinli0301@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinli Zhou, MD, PhD</last_name>
      <phone>15168889976</phone>
      <email>zhouxinli0301@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinli Zhou, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Xinli Zhou，MD，PHD</investigator_full_name>
    <investigator_title>Xinli Zhou</investigator_title>
  </responsible_party>
  <keyword>Saxagliptin, prediabetes, glucose intolerance,obesity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
